Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-23 00:13 CEST (UTC+2h)

Levothyroxine Sample size and study design [Power / Sample Size]

posted by lakshmiprasad - India, 2018-04-14 12:55  - Posting: # 18681
Views: 756

(edited by Ohlbe on 2018-04-16 10:31)

Dear All,

Good Evening,

Here I gone through the all Guidelines, I understood Now because NTI nature (https://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm292676.pdf), We are going to do the Fully replicate.

Thank you very much for your guidence.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,190 registered users;
online 16 (0 registered, 16 guests [including 15 identified bots]).

[The] impatience with ambiguity can be criticized in the phrase:
absence of evidence is not evidence of absence.    Carl Sagan

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed